

## 胸中段食管癌调强放疗近期疗效观察

孙军, 张强, 祝晨, 张磊磊, 马佳铭

237005安徽六安, 安徽医科大学附属六安医院肿瘤中心放疗科

Observation of Short-term Efficacy of Intensity-modulated Radiotherapy for Middle Thoracic Esophageal Carcinoma

Sun Jun, Zhang Qiang, Zhu Chen, Zhang Leilei, Ma Jiaming

Department of Radiation Oncology, The Liu' an Hospital of Anhui Medical University, Liu' an 237005, China

- 摘要
- 参考文献
- 相关文章

全文: [PDF \(965 KB\)](#) [HTML \(1 KB\)](#) 输出: [BibTeX](#) | [EndNote \(RIS\)](#) [背景资料](#)

### 摘要 目的

探讨胸中段食管癌调强放射治疗(IMRT)的近期疗效及不良反应。方法采用IMRT方法,治疗胸中段食管癌41例,单次分割剂量为每次2.0 Gy, 1次/天, 5次/周。总剂量50~68 Gy。结果治疗结束、治疗后3月总有效率(CR+PR)分别为95.1%、92.7%。仅4例3级急性放射性食管炎、2例3级白细胞减少,余不良反应均为0~2级。结论IMRT治疗胸中段食管癌患者可获得局部控制率,不良反应轻,在一定范围内安全可靠,有利于食管癌根治放疗的顺利进行。

关键词: 食管肿瘤 放射治疗 调强放疗 预后

Abstract: Objective

To evaluate the short-term effect and adverse reactions of IMRT for middle thoracic esophageal carcinoma. Methods Forty-one patients with middle thoracic esophageal carcinoma received IMRT with total prescription dose of 50~68 Gy and with 25~34 fractions. 2.0 Gy/fraction, 5 fractions/week. Results The overall response rate was 95.1% after radiotherapy and 92.7% 3 month respectively. The toxicities were acceptable except four patient with grade III esophagitis and two patient with grade III leukocytopenia. Conclusion The local control rate of middle thoracic esophageal carcinoma treated with IMRT was encouraging and this treatment was safe and reliable which might guarantee the completion of IMRT.

Key words: [Esophageal tumor](#) [Radiotherapy](#) [IMRT](#) [Prognosis](#)

收稿日期: 2011-06-03; 出版日期: 2011-08-31

通讯作者: 马佳铭, E-mail: [mjmmql@sina.com](mailto:mjmmql@sina.com)

作者简介: 孙军(1979-),男,本科,住院医师,主要从事肿瘤放射治疗工作

### 引用本文:

. 胸中段食管癌调强放疗近期疗效观察[J]. 肿瘤防治研究, 2012, 39(3): 318-320.

. Observation of Short-term Efficacy of Intensity-modulated Radiotherapy for Middle Thoracic Esophageal Carcinoma[J]. CHINA RESEARCH ON PREVENTION AND TREATMENT, 2012, 39(3): 318-320.

### 服务

[把本文推荐给朋友](#)  
[加入我的书架](#)  
[加入引用管理器](#)  
[E-mail Alert](#)  
[RSS](#)

### 作者相关文章

- [1] Shao LF, Wang QZ. Esophageal surgery new version [M]. Shijiazhuang: Hebei Ke Xue Ji Shu Chu Ban She, 2002: 537-575. [邵令方, 王其彰. 新编食管外科学 [M]. 石家庄: 河北科学技术出版社, 2002: 537-575.]
- [2] Yin WB, Gu XZ. Radiation therapy oncology [M]. 3th edition. Beijing: Zhongguo Xie He Yi Ke Da Xue Chu Ban She, 2002: 606.
- [3] Chu Ban She, 2002: 606.

- [5] [殷蔚伯, 谷铣之.肿瘤放射治疗学 [M]. 3版.北京:中国协和医科大学出版社, 2002: 606.]
- [6] Sabin L H, Wittekind C. International Union Against Cancer. TNM classification of malignant tumors
- [7] 6th edition. New York: Wiley Liss, 2002:131-138.
- [8] Yu JM, Yin WB, Li BS. Accurate radiation therapy oncology [M]. Jinan: Shan Dong Ke Xue Ji Shu Chu
- [9] Ban She. 2003;701. [于金明, 殷蔚伯, 李宝生.肿瘤精确放射治疗学 [M]. 济南:山东科学技术出版社, 2003:701.]
- [10]
- [11] Li CY, Liu M, Zhang JJ, et al. Assessment of diagnostic criterion for mediastinal lymphnode metastasis of esophageal carcinoma [J]. Zhongguo Yi Xue Ying Xiang Ji Shu, 2002, 18(11):1125-1127.
- [12] [李彩英, 刘明, 彭俊杰, 等.胸段食管癌纵隔淋巴结转移诊断标准的探讨 [J]. 中国医学影像技术, 2002, 18:1125-1127.]
- [13] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy [J]. J Clin Oncol, 2002, 20(5): 1167-1174.
- [14] Wang J, Zhu SC, Han C, et al. Significance of microscopic extention from 1162 esophageal carcinoma specimens [J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2007, 16(1):6-9.
- [15] [王军, 祝淑钗, 韩春, 等.1162例食管癌病理标本亚临床病灶范围的研究 [J]. 中华放射肿瘤学杂志, 2007, 16:6-9.]
- [16] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National
- [17] Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst, 00, 92(3): 205-216.
- [18] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and
- [19] the European Organization for Research and Treatment of Cancer (EORTC) [J]. Int J Radiat Oncol Biol
- [20] Phys, 1995, 31(5):1341-1346.
- [21] Yang MS, Wu ZX, Wang JJ, et al. Ten year survival of 1160 esophageal cancer patients treated by
- [22] radiotherapy [J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 1992, 1(3):174-177.
- [23] [杨民生, 五兆星, 王经建, 等.1160例食管癌放射治疗10年疗效[J].中华放射肿瘤学杂志, 1992, 1(3):174-177.]
- [24] Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated
- [25] radiation therapy for primary nasopharynx cancer [J]. Int J Radiat Oncol Biol Phys, 2001, 49(3): 3-632.
- [26] Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated
- [27] conformal radiotherapy improves the outcome of localized prostate cancer [J]. J Urol, 2001, 166(3): 6-881.
- [28] Xiao ZF, Zhang Z, Zhang HZ, et al. Assessment of tumor dose distribution in three dimensional
- [29] conformal radiotherapy treatment planning system for esophageal cancer [J]. Zhonghua Fang She Zhong
- [30] Liu Xue Za Zhi, 2004, 12(4):273-277.
- [31] [肖泽芬, 章众, 张红志, 等.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布 [J]. 中华放射肿瘤学杂志, 2004, 12(4):273-277.]
- [32] Wang XL, Zhao YH, Li JC, et al. The clinical observation of intensity-modulated radiotherapy
- [33] for esophageal carcinoma [J]. Shi Yong Ai Zheng Za Zhi, 2009, 24(6):608-611.
- [34] [王笑良, 赵云辉, 李建成, 等.食管癌束流调强放射治疗的临床疗效观察 [J]. 实用癌症杂志, 2009, 24:608-611.]
- [35] Wang J, Han C, Li XN, et al. Short-term efficacy on intensity-modulated radiotherapy on
- [36] esophageal carcinoma [J]. Ai Zheng, 2009, 28(11):1138-1142.

- [50] [王军, 韩春, 李晓宁, 等.食管癌调强放疗治疗初期疗效分析 [J].*癌症杂志*.2009, 28(11):1138-1142.]
- [51] Zhou ZG, Gao XS, Zhang P, et al.Cox regression analysis of factors related to prognosis of
- [52] esophageal cancer after radiotherapy [J].*Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi*, 2006(5):496-
- [53] 498.
- [54] [周志国, 高献书, 张萍, 等.食管癌放疗后Cox模型多因素分析 [J].*中华放射医学与防护杂志*, 2006, 26
- [55] :496-498.]
- [56] Kishi K, Doki Y, Miyata H, et al.Prediction of the response to chemoradiation and prognosis in
- [57] oesophageal squamous cancer [J].*Br J Surg*, 2002, 89(5): 597-603.
- [58] Imdahl A, Bognar G, Schulte-M nting J, et al.Predictive factors for response to neoadjuvant
- [59] therapy in patients with oesophageal cancer [J].*Eur J Cardiothorac Surg*.2002, 21(4): 657-663.
- [60] Giraud P, De Rycke Y, Rosenwald JC, et al.Conformal radiotherapy planning for lung cancer:
- [61] analysis of set-up uncertainties [J].*Cancer Invest*, 2007, 25(1): 38-46.
- [1] 肖宇, 李惠平, 雷玉涛, 赵红梅, 王晶. 178例三阴性乳腺癌的临床病理特征及生存分析[J].*肿瘤防治研究*, 2012, 39(4): 412-416.
- [2] 王永涛, 孙小亮, 崔玉忠, 赵如森. microRNA-130a在非小细胞肺癌中的表达及其意义[J].*肿瘤防治研究*, 2012, 39(3): 278-280.
- [3] 朱燕, 杨其昌, 刘宏斌, 刘曼华, 张晓娟, 沈屹. D2-40和生存素在宫颈癌中的表达及与预后的相关性[J].*肿瘤防治研究*, 2012, 39(3): 307-311.
- [4] 孙国贵, 胡万宁, 于秀荣, 李成林, 杨从容, 王雅棣. 丁酰亚磺酰亚胺联合放射线对食管癌细胞株TE-1的增敏效应[J].*肿瘤防治研究*, 2012, 39(3): 245-249.
- [5] 姚元虎, 章龙珍, 吴阳, 辛勇, 唐天友, 王建设, 张鑫君, 覃朝晖. 紫杉醇联合放疗治疗局部晚期非小细胞肺癌的疗效观察[J].*肿瘤防治研究*, 2012, 39(3): 321-323.
- [6] 龚益平;漆楚波;王明伟;陈创;赵德绵;许娟;邵军;程洪涛;夏和顺. 三阴性乳腺癌的预后与上皮间叶转化的相关性[J].*肿瘤防治研究*, 2012, 39(2): 173-176.
- [7] 罗平;罗浩军;杨光伦;涂刚. 新型雌激素受体GPER在乳腺癌组织中的表达及与预后的相关性[J].*肿瘤防治研究*, 2012, 39(2): 181-184.
- [8] 王艳阳;折虹;丁皓;詹文华. Basal-like型乳腺癌临床特征与生存分析[J].*肿瘤防治研究*, 2012, 39(2): 177-180.
- [9] 朱红波;龙志国;李凯;贾国凤;张睿. 整合素 $\alpha 3\beta 1$ 在食管鳞状细胞癌组织中的表达及意义[J].*肿瘤防治研究*, 2012, 39(2): 195-197.
- [10] 张建文;吴敬波. 原发性中枢神经系统肿瘤颅外转移状况[J].*肿瘤防治研究*, 2012, 39(2): 238-240.
- [11] 王继云;张俊权;张建伟;王建军;刘本刚;李万刚. 慢性复合应激对食管肿瘤大鼠模型细胞免疫及肿瘤标志物的影响[J].*肿瘤防治研究*, 2012, 39(1): 28-31.
- [12] 裴新红;杨振;姜丽娜. 淋巴结分类情况下不同类型三阴性乳腺癌的预后分析[J].*肿瘤防治研究*, 2012, 39(1): 51-53.
- [13] 孙建建;李胜棉;赵松;李光辉;王小玲. Survivin和Caspase-3在胰腺癌组织中的表达及与预后的关系[J].*肿瘤防治研究*, 2012, 39(1): 62-67.
- [14] 黄东兰;谢菲;岑东芝;张积仁. 2001—2010年乳腺癌预后基因临床研究文献的计量学分析[J].*肿瘤防治研究*, 2012, 39(1): 91-94.
- [15] 姚伟荣综述;马林审校. 放疗联合树突状细胞治疗恶性肿瘤的研究进展[J].*肿瘤防治研究*, 2012, 39(1): 113-115.